Deer Timothy R, Hunter Corey W, Mehta Pankaj, Sayed Dawood, Grider Jay S, Lamer Tim J, Pope Jason E, Falowski Steven, Provenzano David A, Esposito Michael F, Slavin Konstantin V, Baranidharan Ganesan, Russo Marc, Jassal Navdeep S, Mogilner Alon Y, Kapural Leo, Verrills Paul, Amirdelfan Kasra, McRoberts W Porter, Harned Michael E, Chapman Kenneth B, Liem Liong, Carlson Jonathan D, Yang Ajax, Aiyer Rohit, Antony Ajay, Fishman Michael A, Al-Kaisy Adnan A, Christelis Nick, Levy Robert M, Mekhail Nagy
Spine and Nerve Center of the Virginias, Charleston, West Virginia.
Ainsworth Institute of Pain Management, New York, New York.
Pain Med. 2020 Aug 1;21(8):1581-1589. doi: 10.1093/pm/pnaa005.
To conduct a systematic literature review of dorsal root ganglion (DRG) stimulation for pain.
Grade the evidence for DRG stimulation.
An international, interdisciplinary work group conducted a literature search for DRG stimulation. Abstracts were reviewed to select studies for grading. General inclusion criteria were prospective trials (randomized controlled trials and observational studies) that were not part of a larger or previously reported group. Excluded studies were retrospective, too small, or existed only as abstracts. Studies were graded using the modified Interventional Pain Management Techniques-Quality Appraisal of Reliability and Risk of Bias Assessment, the Cochrane Collaborations Risk of Bias assessment, and the US Preventative Services Task Force level-of-evidence criteria.
DRG stimulation has Level II evidence (moderate) based upon one high-quality pivotal randomized controlled trial and two lower-quality studies.
Moderate-level evidence supports DRG stimulation for treating chronic focal neuropathic pain and complex regional pain syndrome.
对背根神经节（DRG）刺激治疗疼痛进行系统的文献综述。
对DRG刺激的证据进行分级。
一个国际跨学科工作组对DRG刺激进行了文献检索。对摘要进行审查以选择进行分级的研究。一般纳入标准为前瞻性试验（随机对照试验和观察性研究），且不属于更大或先前报告过的组。排除的研究为回顾性研究、样本量过小的研究或仅以摘要形式存在的研究。使用改良的介入性疼痛管理技术-可靠性质量评估和偏倚风险评估、Cochrane协作网偏倚风险评估以及美国预防服务工作组证据水平标准对研究进行分级。
基于一项高质量的关键随机对照试验和两项质量较低的研究，DRG刺激具有II级证据（中等）。
中等水平的证据支持DRG刺激用于治疗慢性局灶性神经性疼痛和复杂性区域疼痛综合征。
